Metabolic heterogeneity affects trastuzumab response and survival in HER2-positive advanced gastric cancer.

ABSTRACT:

Background

Trastuzumab is the only first-line treatment targeted against the human epidermal growth factor receptor 2 (HER2) approved for patients with HER2-positive advanced gastric cancer. The impact of metabolic heterogeneity on trastuzumab treatment efficacy remains unclear.

Methods

Spatial metabolomics via high mass resolution imaging mass spectrometry was performed in pretherapeutic biopsies of patients with HER2-positive advanced gastric cancer in a prospective multicentre observational study. The mass spectra, representing the metabolic heterogeneity within tumour areas, were grouped by K-means clustering algorithm. Simpson's diversity index was applied to compare the metabolic heterogeneity level of individual patients.

Results

Clustering analysis revealed me

SUBMITTER: Wang J 

PROVIDER: S-EPMC10951255 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature